

**Invokana (canagliflozin)** in comparison to a sugar pill, for adults with type 2 diabetes mellitus who are uncontrolled with diet and exercise.

#### What is this drug for?

Invokana is used to lower blood sugar along with diet and exercise in the treatment of type 2 diabetic adults.

#### Who might consider taking it?

Adults, ages 18 years or older, with type 2 diabetes whose blood sugar levels have not decreased with diet and exercise and/or with the addition of another anti-diabetic medication.

#### Recommended monitoring:

You should talk to your doctor if you have kidney impairment or disease. Your doctor will monitor potassium in your blood and blood sugar, especially if you are taking a medication that causes low blood sugar.

#### What I should keep in mind:

- You may experience dehydration (which may cause you to feel dizzy, faint or weak especially when you stand up), increased frequency in urination particularly at night, and increased urinary tract or yeast infections.
- Continue the diet and exercise program as instructed by your provider while taking Invokana.
- Continue to check your blood sugar as instructed by your provider while taking Invokana.

#### How long has Invokana been in use?

The FDA approved the drug in March of 2013.

## Invokana Study Findings<sup>1</sup>

587 patients with type 2 diabetes mellitus who were uncontrolled on diet and exercise were randomized to receive Invokana 100 mg, Invokana 300 mg or placebo (sugar pill) for 26 weeks. Here's what happened:

What difference did Invokana make?	People given a sugar pill	People given Invokana 100 mg	People given Invokana 300 mg
<b>Did Invokana help?</b>			
More Invokana users achieved a hemoglobin A1C <7%	21%	45%	62%
<b>What side effects did Invokana users experience?</b>			
More Invokana users experienced urinary tract infections (UTIs)	4.2%	7.2%	5.1%
More men using Invokana experienced yeast infections of the penis	0%	2.5%	5.6%
More women using Invokana experienced vaginal yeast infections	3.8%	8.8%	7.4%
More Invokana users experienced increased frequency and volume of urination	0%	0%	3.0%

Uncertainties: Safety and Efficacy has not been determined yet in Type 1 Diabetes, in children under 18 years of age and pregnant women, therefore, Invokana is not indicated for these populations.

References:

References:

1. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet exercise. *Diabetes Obes Metab* 213;15:372-82.
2. The Dartmouth Institute. Prescription Drugs. Available at: <http://tdi.dartmouth.edu/research/engaging/prescription-drugs>. Accessed 7 October 2014.
3. Janssen Pharmaceuticals, Inc. Invokana Package Insert. Titusville, NJ: 2013, March.
4. Janssen Pharmaceuticals, Inc. Invokana MedGuide. Titusville, NJ: 2013, March.
5. Anon. Pharmacists Letter. Stockton, CA: Therapeutic Research Faculty, <http://pharmacistsletter.therapeuticresearch.com/pl/ArticleDD.aspx?cs=STUDENT&s=PL&pt=6&fpt=56&dd=290508&pb=PL>. Accessed 7 October 2014.